THRIVE ACT FAQS
Reactions to these responses and additional questions are encouraged via our contact form. This list will be frequently updated based on this feedback and other developments.
Shortcuts
CORE PURPOSE AND FRAMING
What problem does the THRIVE Act solve?
The THRIVE Act addresses a structural gap in current FDA law: existing pathways evaluate products that treat a defined disease, usually one condition at a time, rather than products meant to delay or prevent multiple age-related chronic diseases by acting on aging biology itself. Without a fit-for-purpose pathway, sponsors have limited ability to secure FDA-recognized healthspan claims, investors have weak incentives to finance long-horizon prevention trials, and promising interventions remain trapped between academic science and commercial development. THRIVE creates the missing regulatory and incentive infrastructure.
Why can’t FDA simply approve anti-aging products today?
Although FDA has broad authority to interpret and apply the food and drug laws, it does not currently recognize biological aging as a standalone clinical indication with settled evidentiary standards. Existing approval frameworks typically apply to treating or preventing a specific disease in a defined population, whereas healthspan products are aimed at healthy or pre-disease individuals and seek to affect several age-related conditions at once. The agency lacks fit-for-purpose endpoints, biomarker validation frameworks, and evidentiary standards appropriate for this population and purpose.
Why not simply declare aging a disease?
Treating aging as a disease would be an incomplete fix because the real barriers are institutional and structural, not just semantic. Even if aging were reframed as a clinical indication within FDA doctrine, the agency would still need fit-for-purpose endpoints, biomarker validation pathways, new review infrastructure, meaningful incentive structures, and a coherent framework for multi-disease healthspan claims. Simply relabeling aging would supply none of those things.
What is healthspan under THRIVE?
Healthspan is defined as the period of life free from major age-related chronic diseases and disabilities. In general, a product is treated as increasing healthspan if it prevents or reverses two or more major age-related chronic diseases on the basis of a demonstrated effect on the biology of aging.
Why does THRIVE generally require an effect on two or more major age-related diseases?
Aging biology acts upstream of multiple chronic diseases at once—the same molecular processes that drive cardiovascular disease also drive neurodegeneration, frailty, metabolic dysfunction, and cancer. A genuine healthspan product should therefore ordinarily affect more than one major age-related condition. The two-disease floor distinguishes THRIVE products from ordinary single-disease preventives and anchors the pathway in the idea of shared biological drivers rather than disease-by-disease label expansion. However, the new proposed Center for Healthspan Products could have the discretionary authority to qualify products strongly connected to aging biology even where the effect is framed through a single disease.
Why is comprehensive legislation proposed instead of smaller FDA-only reforms?
FDA can improve parts of the landscape through guidance, biomarker qualification work, or new meeting structures, but it cannot by itself create the bill's core statutory features: claim exclusivity, transferable priority review vouchers, innovation prizes, private enforcement rights, and mandated FDA-CMS collaboration. These features require an act of Congress. Legislation also provides the durable commitment and funding authority necessary to build the Center for Healthspan Products and sustain the long-term evidence generation that healthspan development demands.
What is the economic and public-health case for THRIVE?
Chronic age-related disease is the dominant driver of disability, caregiver burden, and public and private health spending in the United States. Life expectancy now lags behind peer nations, with sharp disparities by income and geography. Even modest delay or prevention of multimorbidity could produce outsized social returns—saving trillions in Medicare and Medicaid spending, reducing disability, and sustaining workforce participation. The current market and regulatory system underinvest in such prevention because evidence generation is costly, lengthy, and commercially uncertain without the infrastructure THRIVE creates.
HOW THE THRIVE PATHWAY WOULD WORK
How does THRIVE's tiered approval system work?
THRIVE creates a three-tier evidence structure. Tier 1 permits a claim that a product is reasonably likely to increase healthspan based on early, multimodal evidence. Tier 2 requires stronger intermediate clinical evidence that the product likely increases healthspan. Tier 3 requires substantial evidence from adequate and well-controlled studies showing that the product definitively increases healthspan in a defined population. Evidence requirements, post-market obligations, and incentives all intensify as a product advances through the tiers.
Does a sponsor have to go through all three tiers in sequence?
No. A sponsor with sufficiently strong evidence may enter at Tier 2 or Tier 3 directly, and a sponsor with a Tier 1 approval may later move directly to Tier 3 if the data support it. The staged framework is a flexible on-ramp for development, not a mandatory multi-step ladder for every product. The reason why a sponsor that has the requisite data might skip a tier or two is to earlier access a broader market that a higher tier approval might open up.
What evidence is contemplated at each tier?
Tier 1 may rely on a broad evidentiary package, including mechanistic studies, in vitro or in silico models, animal data, biomarker evidence, epidemiology, real-world evidence, and early human clinical data from studies of at least 10 weeks. Tier 2 requires more robust clinical trial evidence, including at least 26 weeks of trial data and statistically significant effects on validated biomarkers or surrogate endpoints. Tier 3 uses the familiar substantial-evidence standard applied in traditional drug approval and requires well-controlled studies demonstrating actual healthspan benefit.
What happens if a product fails to advance to the next tier?
A Tier 1 or Tier 2 product that fails to generate sufficient evidence will have its healthspan claim withdrawn or its labeling modified to reflect the limitation of available evidence, with a period for appeal and submission of additional data. Failure to advance the THRIVE claim does not affect a separate disease-treatment approval or ordinary supplement structure/function marketing under DSHEA.
How practical is it to expect a marketed THRIVE product to be pulled from the market if it fails to advance?
In case of failure to advance to a higher tier, the new Center for Healthspan Products has discretion to require steps such as label revision, claim withdrawal, narrowed indicated populations, and stepped-up surveillance, as well as suspension from the market. A product that also carries a traditional disease indication, or a supplement marketable under DSHEA, can stay on the market, without the healthspan claim. A product that has been marketed has accumulated more efficacy and safety data than were available at the time of approval for a particular tier. If a product demonstrates commercial relevance, then a suspension from market until satisfactory additional safety and efficacy data are available need not give regulators pause.
What kinds of products are covered?
THRIVE is intentionally broad, covering drugs, biologics, medical devices, dietary supplements, and combination products. That breadth reflects the reality that meaningful healthspan interventions may involve therapeutics, diagnostics, wearables, monitoring tools, and evidence-based nutritional products rather than a single modality.
Does THRIVE replace existing FDA pathways?
No. THRIVE is additive and optional, not a substitute for traditional disease-treatment or disease-prevention pathways. Sponsors may continue to use existing drug, biologic, device, or supplement frameworks regardless of whether they ever pursue a THRIVE claim. No existing approval pathway is altered or removed.
FDA INFRASTRUCTURE AND REGULATORY DESIGN
What new FDA processes and structures would THRIVE create?
THRIVE establishes a Center for Healthspan Products within FDA, a specialized advisory committee, Type H development meetings, a Breakthrough Healthspan Product designation, and guidance on biomarkers, trial design, and real-world evidence. The goal is to give sponsors a dedicated home inside FDA for products that do not fit cleanly within current disease-centered review silos.
What are Type H meetings intended to do?
Type H meetings are specialized development meetings tailored to the scientific and regulatory issues unique to healthspan products, covering strategy, endpoints, pre-application planning, risk evaluation, and other emerging issues. They provide a practical mechanism to reduce uncertainty, accelerate problem-solving, and create a more predictable interface between sponsors and the agency—analogous to the familiar Type B and Type C meeting structures but calibrated to healthspan development.
What is the Breakthrough Healthspan Product designation?
THRIVE establishes a Breakthrough Healthspan Product designation to expedite development and review for especially promising products. It is analogous in logic to existing FDA breakthrough programs but is tailored to prevention-oriented products, biomarkers, and healthspan-related evidence generation, including novel endpoint and real-world evidence approaches.
How would THRIVE handle biomarkers and surrogate endpoints when the field is still developing?
Biomarker validation and product development must proceed together, because waiting for decades-long hard outcomes would make most healthspan programs commercially nearly impossible. The Center for Healthspan Products and associated guidance are therefore tasked with building the endpoint and biomarker framework over time, in parallel with the development of the first generation of healthspan products. Tier 1 approval can be based on a combination of preclinical, mechanistic, and early clinical evidence—not a single definitive endpoint—so that biomarker development advances alongside product development. By Tier 3, sponsors must demonstrate effects on validated endpoints or surrogates.
Why is the tiered model disciplined rather than permissive?
THRIVE adapts familiar regulatory logic rather than inventing a wholly foreign model. Earlier market access is permitted only where evidence generation continues and FDA retains full authority over labeling, surveillance, and withdrawal. Tier 1 is not final proof, Tier 2 is not the end of the inquiry, and Tier 3 remains the point at which traditional substantial evidence must be demonstrated. The escalating obligations at each tier ensure that the framework is self-reinforcing rather than self-diluting.
INCENTIVES, EXCLUSIVITY, AND INTELLECTUAL PROPERTY
What financial incentives does THRIVE offer?
THRIVE provides four main incentive categories: (1) claim exclusivity of five years per tier, for up to 15 years cumulative; (2) transferable Priority Review Vouchers for Tier 2 and Tier 3 approvals; (3) Prevention Impact Exclusivity (3 additional years) and Population Health Exclusivity (2 additional years) for products with broad societal benefit; and (4) up to five Healthspan Innovation Prizes of $100 million each for breakthrough prevention or rejuvenation products.
Why is exclusivity tied to the claim rather than to the underlying molecule or platform?
THRIVE is designed to reward the generation of evidence needed to support an FDA-recognized healthspan claim, rather than granting monopoly control over an ingredient, as is the purview of patent law. Another firm may market the same underlying compound under a different lawful framework, but cannot make the protected THRIVE claim without generating independent qualifying evidence or waiting for exclusivity to expire. This structure incentivizes evidence generation without blocking access to underlying compounds.
Why are Priority Review Vouchers included?
Priority Review Vouchers are an immediately monetizable pull incentive that can attract investors to long-horizon prevention programs before reimbursement markets are mature. A PRV grants its holder—or any purchaser—expedited FDA review of any drug application, historically worth well in excess of $100 million on secondary markets. THRIVE draws on the proven precedent of rare disease and neglected tropical disease voucher programs, which have successfully funded scientifically worthy but commercially difficult development programs.
Why not solve the incentive problem by extending patents or other IP rights instead?
A patent-extension approach would require changes to additional legal regimes and could implicate broader patent-policy and treaty-related questions, adding significant complexity. THRIVE's claim-based exclusivity functions as a regulatory tool that protects the value of newly generated evidence without reopening the entire patent framework or depending on whether the underlying molecule remains patentable. This builds on existing non-patent incentives of regulatory exclusivity such as in orphan drugs and Waxman-Hatch exclusivity for new and repurposed molecules. That distinction is especially important for repurposed generics and supplements, where traditional IP may be weak or unavailable (and complicated to extend, for long-known compounds) even when the evidence-generation burden is substantial.
How does THRIVE interact with patents and existing regulatory exclusivity?
THRIVE claim exclusivity exists independently of patents and other regulatory exclusivities, such as new chemical entity or pediatric exclusivity. A patented product may hold both conventional IP protection and THRIVE claim exclusivity simultaneously. An off-patent or generic product may still obtain THRIVE-specific market protection if it generates the necessary evidence, which is precisely the incentive structure needed to unlock investment in repurposed compounds.
Is this just a giveaway to the pharmaceutical industry?
No. THRIVE is designed to correct a market failure in prevention and is intended to benefit emerging companies, repurposed generics, supplement developers, and device innovators as well as larger pharmaceutical firms, and ultimately the public. Today there is no private-sector incentive to run rigorous clinical trials on low-cost generics like metformin or rapamycin for healthspan, or to generate robust evidence for supplements. THRIVE creates a structured return on that investment by conferring regulatory exclusivity on claims, not monopoly rights over molecules. It is modeled on prior public-private frameworks—the Orphan Drug Act, the 21st Century Cures Act, the PRV program—that have successfully catalyzed development the market would otherwise not fund.
SUPPLEMENTS, DEVICES, AND RESEARCH UTILITY
Why does THRIVE include dietary supplements?
Some compounds currently sold as supplements may have genuine healthspan effects, but sponsors today have little reason to invest in rigorous trials when the resulting evidence cannot support FDA-recognized claims and may freely be copied by competitors. THRIVE offers a voluntary, higher-evidence pathway for supplement developers who want to make evidence-based healthspan claims—giving them the same tiered approval system, the same exclusivity, and the same evidence incentives as drug developers.
Does THRIVE change DSHEA or ordinary supplement regulation?
No. THRIVE does not repeal, narrow, or replace DSHEA, and supplement firms not seeking THRIVE claims may continue operating under current law exactly as before. The only restriction is that firms outside the THRIVE pathway may not use or imply an exclusivity-protected THRIVE claim while it remains in force.
Would a THRIVE healthspan pathway provide enough incentive for supplement manufacturers to spend money generating the required clinical evidence?
For a number of supplement manufacturers, yes. The pathway is most likely to attract companies pursuing premium, clinically differentiated products, firms seeking to distinguish themselves from commodity competitors, and sponsors willing to trade higher evidence and surveillance obligations for stronger claims and temporary exclusivity. Purely volume-driven sellers comfortable under DSHEA's lower-evidence structure/function regime may not participate, and that is by design: THRIVE creates an optional premium evidence pathway rather than converting the entire supplement industry.
Why does THRIVE include devices and combination products?
Biomarker measurement, monitoring, diagnostics, and physiologic intervention tools are integral to any serious healthspan ecosystem. Healthspan biomarkers are essential to validating drugs, and validating biomarkers requires devices to measure them. THRIVE's inclusion of devices creates a virtuous bootstrapping cycle: device-measured biomarkers validate drugs, and drug trials validate devices as biomarker platforms. The proposal also explicitly contemplates multi-agent regimens, because aging biology may be addressed more effectively through combinations than through single products alone.
How would THRIVE help researchers, not just commercial sponsors?
THRIVE gives academic and translational researchers more evidence-based interventions, biomarkers, monitoring tools, trial designs, and regulatory engagement mechanisms with which to study aging biology and multimorbidity prevention. The Center for Healthspan Products, its advisory structures, and the evidence-generation model are also designed to help convert federally funded or philanthropically supported work into development programs with clearer downstream pathways, rather than leaving promising findings stranded without translational follow-through.
How would THRIVE affect academic geroscience and studies like TAME?
THRIVE creates pull incentives for biomarker studies, repurposed-drug trials, cohort-based aging research, and public-private translational work. Results from trials such as TAME, if funded and successfully completed, could serve as foundational evidence for a sponsor's THRIVE application, provided the sponsor takes on the subsequent safety and development obligations needed to advance the program. By creating a credible downstream pathway, THRIVE raises the value of upstream academic research in aging biology.
SAFETY, COVERAGE, AND ENFORCEMENT
How does THRIVE address safety for products used in healthy people?
Every THRIVE product must be shown safe for use under its labeling conditions, and preventive use in healthy or pre-disease populations warrants heightened review and pharmacovigilance. Tier 1 and Tier 2 sponsors must submit registry protocols and active surveillance plans, monitor adverse events of special interest, and file periodic safety updates more frequently than for disease-treatment products. THRIVE preserves FDA's full authority to calibrate safety requirements by product type, tier, and evidentiary maturity, and to withdraw or modify claims where safety concerns arise.
Does THRIVE lower safety standards precisely for the young and healthy population that should require the greatest caution?
No. THRIVE changes when and how efficacy can be inferred, not the standard of safety required for the labeled use. Safety must remain adequate regardless of tier, and post-market monitoring obligations are strengthened—not relaxed—for preventive populations. The most defensible design includes robust premarket safety packages, mandatory rather than discretionary surveillance elements, narrower early-tier indicated populations, and clear labeling about the evidentiary status of the product at each tier, so that prescribers, patients, and payers can make fully informed decisions.
Could Tier 1 function more as a marketing designation than as meaningful proof?
Tier 1 is expressly not a final demonstration of healthspan benefit. It is a conditional, temporary authorization tied to continued evidence generation and subject to modification or withdrawal if the sponsor does not progress. Precise labeling, disciplined endpoint selection, and credible enforcement of advancement obligations are all integral to THRIVE's design to ensure that Tier 1 functions as a genuine on-ramp to rigorous evidence, not as a permanent marketing asset based on early data.
Will payers cover Tier 1 and Tier 2 products?
Coverage decisions ultimately rest with payers, and mandated FDA-CMS collaboration and parallel review are included in THRIVE precisely because approval without coverage often produces little real-world access. Tier 3 products will have the strongest coverage case, while earlier-tier products may face restricted coverage, high evidentiary thresholds, or coverage-with-evidence-development approaches. THRIVE's parallel review framework is intended to help sponsors design programs with both approval and reimbursement in view from the outset. At the same time, post-approval coverage decisions are not givens; the driver is evidence, and THRIVE is designed to incentivize the generation of more healthspan evidence. At the same time, politics and society need to continuously calibrate the balance between preventive and disease treatment approaches, between short term and long term costs and savings and other benefits.
How does THRIVE try to address the approval-versus-coverage gap?
THRIVE requires an FDA-CMS framework for parallel review, joint guidance, and coordination around evidence and post-market issues. The goal is that sponsors can design development programs with both approval and reimbursement in view, rather than obtaining FDA recognition first and only later discovering that the evidence is insufficient for coverage decisions. Joint guidance on what constitutes adequate evidence for both agencies reduces duplicative effort and accelerates patient access.
What is the private right of action, and why is it included?
THRIVE allows exclusivity holders to sue entities making unauthorized healthspan claims during the exclusivity period and to seek injunctions, damages, enhanced damages for willful misconduct, and attorney fees. Currently, such enforcement is the responsibility and jurisdiction of the FDA, and FDA alone may not have sufficient resources to police misuse of claims, especially in the supplement context. Private enforcement prevents the free-riding that would otherwise undermine the investment rationale and erode the evidentiary standards the exclusivity system is designed to protect.
Would THRIVE create a tsunami of litigation?
Early in the life of THRIVE, the volume of approved claims will likely be limited, which should constrain the number of viable private suits. That said, a private right of action must be carefully designed: overly broad claim definitions or vague boundaries with existing supplement speech could raise compliance costs and encourage aggressive enforcement by well-capitalized incumbents. The best design, developed over time by the new Center for Healthspan Products, includes tight drafting around what constitutes an infringing healthspan claim, clear safe harbors, and carefully calibrated remedies to ensure private enforcement serves its intended purpose of deterring free-riding rather than becoming an independent barrier to competition.
EQUITY, POLITICS, AND IMPLEMENTATION
How would THRIVE affect health equity and disparities?
Chronic disease burdens fall disproportionately on lower-income, rural, and minority populations, and prevention-oriented healthspan products could have leveraged benefits by reducing disability and multimorbidity earlier in life in those communities. THRIVE's "Population Health Exclusivity" bonus specifically rewards products that reduce health disparities. Its inclusion of generics and supplements also creates pathways for low-cost, widely accessible interventions rather than only high-cost novel biologics. Realizing the equity benefit, however, will require that implementation actively support affordability and uptake in high-burden communities.
Will healthspan products be affordable and covered by insurance?
THRIVE seeks to improve the odds of coverage by linking FDA and CMS earlier in development and by allowing repurposed generics and supplements to enter the framework, which could create lower-cost options alongside branded products. Pricing and reimbursement ultimately depend on market behavior, payer decisions, and broader policy choices that extend beyond THRIVE itself, so affordability cannot be guaranteed by the statute alone. The parallel-review framework and the inclusion of established compounds in the eligible product universe are the principal mechanisms through which THRIVE promotes access.
Won’t insurers just wait until Tier 3 approval to cover products?
The concern is legitimate, and THRIVE does not guarantee coverage at Tier 1 or Tier 2. However, (i) THRIVE provides for an FDA-CMS parallel review framework specifically so that sponsors design their evidence programs with reimbursement requirements in view from the outset, rather than discovering after approval that the evidence is insufficient for coverage; (ii) Tier 1 and Tier 2 approvals are well-suited to Coverage with Evidence Development (CED), a mechanism CMS already uses—under which a product is covered for a defined population contingent on the sponsor continuing to generate outcomes data; (iii) while broad payment coverage would be the ideal for a sponsor, earlier tier approvals enable sponsors to access the market of self-payers (not insignificant for repurposed generics and supplements, and those who can pay out-of-pocket); (iv) earlier access to market than traditional approval accelerates use experience, which can enhance fundability of additional clinical evidence; and (v) unlocks or moves sponsors closer to other incentives, such as exclusivity and vouchers.
What are the main implementation challenges for FDA?
The largest implementation challenge is institutional capacity. FDA will need specialized staff, new expertise in aging biology and biomarker science, multiple guidance documents, surveillance systems, and structured coordination with CMS—all on an ambitious timetable. Explicit appropriations, realistic milestones, and phased implementation are therefore essential to ensuring the proposal is credible and functional in practice rather than aspirational on paper.
Could THRIVE be implemented in phases?
Yes, and phased implementation is a pragmatic approach. A first phase could establish the Center for Healthspan Products, formalize Type H meetings, strengthen biomarker and endpoint development, and build FDA-CMS coordination infrastructure. Broader market-access features and exclusivity provisions could be activated in a subsequent phase once the foundational framework has proven workable and FDA has developed the institutional capacity to administer them effectively.
What additional provisions could strengthen THRIVE?
The most important enhancements include stronger safety guardrails for healthy populations, clearer biomarker and surrogate endpoint standards, explicit funding and staffing authority, more concrete equity and affordability measures, stronger reporting requirements, and closer coordination with NIH and related research programs. Other valuable additions include small-business support provisions, international harmonization work to align with emerging regulatory frameworks abroad, and explicit success metrics reported through FDA-CMS and, where appropriate, GAO.
How should THRIVE be understood at this stage?
THRIVE is a serious and conceptually sophisticated effort to modernize U.S. regulation for healthy longevity and multi-disease prevention. It raises substantial scientific, safety, reimbursement, and operational questions that will require continued engagement with FDA, CMS, Congress, researchers, and industry—and the proposal is designed to evolve through that process. The most accurate characterization is that THRIVE is an ambitious framework-setting proposal: more than a conversation starter, and one that is intended to be refined, strengthened, and phased in a manner that best serves the public health goals it is designed to achieve.